Table 3.

Adverse effects of immunotherapy in study subjects.

Variable	Blinatumomab cohort (n=18)	Inotuzumab cohort (n=14)
Mean number of cycles (range)	1.47 (0.5–4)	1.62 (1–3)
Total complications, n (%)	9 (50.0%)	1 (7.1%)
CRS, n (%)	6 (33.3%)	0
grade 1, n (%)	2 (33.3%)	n/a
grade 2, n (%)	1 (16.7%)	n/a
grade 3, n (%)	2 (33.3%)	n/a
grade 4, n (%)	1 (16.7%)	n/a
Neurotoxicity, n (%)	4 (22.2%)	0
grade 2, n (%)	3 (75.0%)	n/a
grade 4, n (%)	1 (25.0%)	n/a
HSCT following immunotherapy, n (%)	13 (72.2%)	5 (35.7%)
SOS post-HSCT, n (%)	1 (7.7%)	1 (20.0%)

Note bene: This table contains 5 patients who received both blinatumomab and inotuzumab. Percentage of SOS post-HSCT refers to total number of patients who underwent HSCT in each cohort.